Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025)
Historic Income from Continuing Operations for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.8 million.
- Benitec Biopharma's Income from Continuing Operations fell 9010.37% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 7825.91%. This contributed to the annual value of -$38.5 million for FY2025, which is 7825.91% down from last year.
- Latest data reveals that Benitec Biopharma reported Income from Continuing Operations of -$8.8 million as of Q2 2025, which was down 9010.37% from -$14.5 million recorded in Q1 2025.
- In the past 5 years, Benitec Biopharma's Income from Continuing Operations ranged from a high of -$3.5 million in Q1 2022 and a low of -$14.5 million during Q1 2025
- Moreover, its 5-year median value for Income from Continuing Operations was -$4.8 million (2021), whereas its average is -$5.8 million.
- As far as peak fluctuations go, Benitec Biopharma's Income from Continuing Operations skyrocketed by 1178.57% in 2024, and later plummeted by 25010.86% in 2025.
- Quarter analysis of 5 years shows Benitec Biopharma's Income from Continuing Operations stood at -$4.8 million in 2021, then fell by 15.95% to -$5.6 million in 2022, then fell by 23.38% to -$6.9 million in 2023, then crashed by 43.98% to -$10.0 million in 2024, then increased by 11.86% to -$8.8 million in 2025.
- Its Income from Continuing Operations was -$8.8 million in Q2 2025, compared to -$14.5 million in Q1 2025 and -$10.0 million in Q4 2024.